drugset / Trial / NCT05043350

Combined Antihistaminics Therapy in COVID 19 Patients

NCT05043350

RandomizedParallel-groupOpen-labelTreatment

Summary

The use of antihistaminic medications could result in a significant immune modulation which may help in the treatment of cytokine storm of COVID-19.Thus, the aim of this study is to evaluate efficacy and safety of famotidine and loratadine combination in covid 19 treatment protocol.

Timeline

Start
2021-09-13
Primary completion
2022-07-30
Completion
2022-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Loratadine Small molecule 10 mg Oral
Background Famotidine Other / unclassified 40 mg Intravenous

Indications